Associated Papers
RET germline mutations drive tumorigenesis but not tumor aggressiveness in MEN 2.
Machens A et al.
Endocrine, 2026
Calcitonin Thresholds for Prediction of Medullary Thyroid Carcinoma and its Clinical Response in MEN2A Gene Carriers.
Prete A et al.
The Journal of Clinical Endocrinology and Metabolism, 2026
Multi-center multi-omics integration predicts individualized prognosis in medullary thyroid carcinoma.
Zhou Y et al.
Nature Communications, 2026
Rare cases in two Chinese MEN2A families with RET C634Y germline mutation-a homozygous female patient and heterozygous identical twins: a systematic review of literature.
Qi XP et al.
Frontiers in Endocrinology, 2026
RET Gene Alterations in Clinical Practice: A Comprehensive Review and Database Update.
Ricciardi Tenore C et al.
Genes, 2025
Real-world efficacy and safety of selpercatinib in RET-mutant medullary thyroid cancer at a Tertiary Referral Center.
Machlah YM et al.
European Journal of Endocrinology, 2025
Geospatial inheritance across the breath of the RET mutational landscape of multiple endocrine neoplasia 2A.
Machens A et al.
Endocrine, 2025
Decoding genomic rearrangements for cancer driver discovery.
Seo E et al.
Molecules and Cells, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Four decades of the RET gene: From discovery to tumor-agnostic therapy.
Takahashi M
Journal of the Formosan Medical Association = Taiwan Yi Zhi, 2025
Discovery of APS03118, a Potent and Selective Next-Generation RET Inhibitor with a Novel Kinase Hinge Scaffold.
Zhong J et al.
Journal of Medicinal Chemistry, 2025
Familial Clinical Heterogeneity of Medullary Thyroid Cancer with Germline RET S891A Protooncogene Mutation: 7-year Follow-up with Successful Sorafenib Treatment
Kızılcan Çetin S et al.
Journal of Clinical Research in Pediatric Endocrinology, 2025
Approach to the Patient: Hereditary Medullary Thyroid Carcinoma.
Shariq OA et al.
The Journal of Clinical Endocrinology and Metabolism, 2025
Incidence and distribution of neck node metastases in hereditary vs. sporadic medullary thyroid cancer at basal calcitonin serum levels ≤100 pg/ml: 30-year experience.
Machens A et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2025
RET Y791F in MEN2: a variant presumed non-pathogenic, yet lacking conclusive evidence of insignificance.
Binter T et al.
Gland Surgery, 2025
Medullary Thyroid Cancer Risk and Mortality in Carriers of Incidentally Identified MEN2A RET Variants.
West CE et al.
Jama Network Open, 2025
Kinome profiling reveals pathogenic variant specific protein signalling networks in MEN2 children with Medullary Thyroid Cancer.
Rix B et al.
Npj Precision Oncology, 2025
Genomic testing for RET in the clinic: UK and global perspective.
Izatt L
Endocrine-related Cancer, 2025
Prioritization of predisposition genes for familial non-medullary thyroid cancer by whole-genome sequencing.
Srivastava A et al.
European Journal of Endocrinology, 2025
An Analysis of Primary Hyperparathyroidism in Individuals Diagnosed with Multiple Endocrine Neoplasia Type 2.
Gheorghe AM et al.
Diseases (basel, Switzerland), 2025
Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma.
Hamidi S et al.
Thyroid : Official Journal of the American Thyroid Association, 2025
Hereditary Medullary Thyroid Cancer: Genotype-Phenotype Correlation.
Frank-Raue K et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer, 2025
Surgical Treatment of Medullary Thyroid Cancer.
Machens A et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer, 2025
Investigating the link between APCI1307K mutation and breast cancer in a Jordanian Arab population.
Sharaf B et al.
Frontiers in Oncology, 2025
Genetic counseling for hereditary cancer syndromes: a 5-year experience from a single center in Bulgaria.
Hachmeriyan M et al.
Oncology Reviews, 2025
Novel Gene Variants in a Nationwide Cohort of Patients with Pheochromocytoma and Paraganglioma.
Martínez de Lapiscina I et al.
International Journal of Molecular Sciences, 2024
Endocrine Perspective of Cutaneous Lichen Amyloidosis: RET-C634 Pathogenic Variant in Multiple Endocrine Neoplasia Type 2.
Florescu AF et al.
Clinics and Practice, 2024
Fundamentals and recent advances in the evaluation and management of medullary thyroid carcinoma.
Gigliotti BJ et al.
Molecular and Cellular Endocrinology, 2024
Thyroid Malignancy and Cutaneous Lichen Amyloidosis: Key Points Amid RET Pathogenic Variants in Medullary Thyroid Cancer/Multiple Endocrine Neoplasia Type 2 (MEN2).
Stanescu LS et al.
International Journal of Molecular Sciences, 2024
Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D.
Zheng Q et al.
Nature Chemical Biology, 2024
Oncological features of sporadic vs. hereditary pediatric medullary thyroid cancer.
Machens A et al.
Endocrine, 2024
RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.
Hamidi S et al.
Annales D'endocrinologie, 2024
Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.
Wang ZX et al.
Journal of Medicinal Chemistry, 2024
Does Genotype-Specific Phenotype in Patients with Multiple Endocrine Neoplasia Type 2 Occur as Current Guidelines Predict?
Binter T et al.
Cancers, 2024
Multiple endocrine neoplasia type 2: towards a risk-based approach integrating molecular and biomarker results.
Machens A et al.
Current Opinion in Oncology, 2024
Unveiling new chapters in medullary thyroid carcinoma therapy: advances in molecular genetics and targeted treatment strategies.
Huai JX et al.
Frontiers in Endocrinology, 2024
Applications of genomic research in pediatric endocrine diseases.
Kim JH et al.
Clinical and Experimental Pediatrics, 2023
Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET.
Sahakian N et al.
Cancers, 2023
Clinic Heterogeneity and Management of Pediatric Patients With Germline RET Proto-oncogene Mutation: Single-center Experience.
Şıklar Z et al.
Journal of Pediatric Hematology/oncology, 2023
Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy.
Steen EA et al.
Biochemical Pharmacology, 2023
Medullary Thyroid Cancer: Updates and Challenges.
Gild ML et al.
Endocrine Reviews, 2023
The Changing Face of Multiple Endocrine Neoplasia 2A: From Symptom-Based to Preventative Medicine.
Machens A et al.
The Journal of Clinical Endocrinology and Metabolism, 2023
From Circulating Tumor Cells to Mirna: New Challenges in the Diagnosis and Prognosis of Medullary Thyroid Cancer.
Ricci C et al.
Cancers, 2023
Looking for RET alterations in thyroid cancer: clinical relevance, methodology and timing.
Elisei R et al.
Endocrine, 2023
Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments.
Martins RS et al.
Journal of Personalized Medicine, 2023